Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials.
CAR-T cells
adoptive cell transfer
engineered TCR
hepatocellular carcinoma
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jan 2021
13 Jan 2021
Historique:
received:
05
12
2020
revised:
07
01
2021
accepted:
08
01
2021
entrez:
16
1
2021
pubmed:
17
1
2021
medline:
17
1
2021
Statut:
epublish
Résumé
The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials.
Identifiants
pubmed: 33450845
pii: cancers13020271
doi: 10.3390/cancers13020271
pmc: PMC7828372
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Immunol Res. 2014 Feb;2(2):154-66
pubmed: 24778279
Mol Ther. 2020 Dec 3;:
pubmed: 33278564
Annu Rev Immunol. 2018 Apr 26;36:247-277
pubmed: 29328785
J Hepatol. 2015 Feb;62(2):486-91
pubmed: 25308176
Front Immunol. 2019 Feb 05;10:128
pubmed: 30804938
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Cancer Immunol Res. 2020 Mar;8(3):309-320
pubmed: 31953246
J Immunother Cancer. 2017 Nov 21;5(1):90
pubmed: 29157300
Aliment Pharmacol Ther. 2012 May;35(10):1113-34
pubmed: 22432733
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Ann Oncol. 2019 Nov 1;30(11):1740-1750
pubmed: 31435646
Hum Gene Ther. 2017 May;28(5):437-448
pubmed: 27530312
J Immunol. 2019 Jul 1;203(1):198-207
pubmed: 31142602
Cell Death Dis. 2018 Feb 15;9(3):282
pubmed: 29449531
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Transplantation. 2002 Dec 27;74(12):1746-51
pubmed: 12499891
Immunol Rev. 1995 Jun;145:61-89
pubmed: 7590831
Leukemia. 2020 Dec;34(12):3228-3241
pubmed: 32111969
Cancer Immunol Res. 2019 Nov;7(11):1813-1823
pubmed: 31484657
N Engl J Med. 2016 Dec 29;375(26):2561-9
pubmed: 28029927
Lancet Oncol. 2004 Jul;5(7):409-18
pubmed: 15231247
Oncoimmunology. 2019 May 25;8(8):1615818
pubmed: 31413924
Mol Ther Nucleic Acids. 2013 Jul 09;2:e105
pubmed: 23839099
Nature. 2013 Sep 19;501(7467):346-54
pubmed: 24048067
Curr Mol Med. 2008 Dec;8(8):784-804
pubmed: 19075676
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Br J Cancer. 2007 Feb 12;96(3):417-23
pubmed: 17211480
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
J Clin Invest. 2020 Jun 1;130(6):3087-3097
pubmed: 32069268
Cancer Immunol Immunother. 2016 Mar;65(3):293-304
pubmed: 26842125
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
Clin Cancer Res. 2013 Feb 15;19(4):920-8
pubmed: 23362325
Clin Cancer Res. 2020 Aug 1;26(15):3979-3989
pubmed: 32371538
Genomics Proteomics Bioinformatics. 2019 Apr;17(2):129-139
pubmed: 31229590
Gastroenterology. 2008 Jan;134(1):239-47
pubmed: 18166356
Hepatology. 1998 Feb;27(2):407-14
pubmed: 9462638
Mol Ther. 2011 Mar;19(3):620-6
pubmed: 21157437
Front Immunol. 2017 Jan 11;7:690
pubmed: 28123387
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Sci Adv. 2020 May 20;6(21):eaaz3223
pubmed: 32637585
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270272
Hepatol Commun. 2020 Aug 09;4(10):1541-1551
pubmed: 33024922
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Hepatology. 2019 May;69(5):2061-2075
pubmed: 30561769
Expert Opin Biol Ther. 2020 May;20(5):503-516
pubmed: 32125191
Clin Cancer Res. 2005 May 1;11(9):3205-9
pubmed: 15867214
Prog Mol Biol Transl Sci. 2019;162:199-212
pubmed: 30905450
Scand J Clin Lab Invest. 1956;8(2):174
pubmed: 13351554
Gastroenterology. 2013 Aug;145(2):456-65
pubmed: 23639914
Nat Immunol. 2018 Mar;19(3):222-232
pubmed: 29379119
Int J Cancer. 1999 Jan 18;80(2):219-30
pubmed: 9935203
Cancer Med. 2020 Jan;9(2):640-652
pubmed: 31800160
Drug Discov Today. 2018 Apr;23(4):758-762
pubmed: 29317339
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Genomics. 2020 Nov;112(6):5101-5114
pubmed: 32941982
J Hepatol. 2017 Sep 18;:
pubmed: 28923358
Cancer. 1999 Mar 15;85(6):1234-40
pubmed: 10189127
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Oncol Lett. 2019 Apr;17(4):3937-3943
pubmed: 30881511
J Hepatol. 2000 Apr;32(4):612-7
pubmed: 10782910
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Nat Med. 2019 Sep;25(9):1408-1414
pubmed: 31477906
Mol Ther. 2020 Oct 14;:
pubmed: 33129371
Histopathology. 2018 Jul;73(1):68-80
pubmed: 29465777
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Front Oncol. 2019 Apr 10;9:248
pubmed: 31024850
Medicine (Baltimore). 2019 Nov;98(48):e17990
pubmed: 31770209
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434
pubmed: 32242094
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Int J Cancer. 2018 Jun 15;142(12):2471-2477
pubmed: 29388206
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Cancer Res. 1994 Jun 1;54(11):2856-60
pubmed: 7514493
Mol Ther Oncolytics. 2016 Apr 13;3:16006
pubmed: 27162934
Hepatology. 2006 Jun;43(6):1284-94
pubmed: 16729333
Nat Commun. 2020 Jan 10;11(1):219
pubmed: 31924795
Blood. 2011 Dec 1;118(23):6050-6
pubmed: 21984804
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Biochem Soc Trans. 2016 Apr 15;44(2):349-55
pubmed: 27068939
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Front Immunol. 2019 May 24;10:1149
pubmed: 31178870
Nat Rev Clin Oncol. 2016 Jan;13(1):25-40
pubmed: 26525683
Sci Rep. 2017 Jan 20;7:39833
pubmed: 28106050
Nat Rev Cancer. 2019 Aug;19(8):465-478
pubmed: 31278396
Hemasphere. 2019 Feb 01;3(1):e172
pubmed: 31723811
Cancer Res. 2009 Jul 15;69(14):5627-9
pubmed: 19584271
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Nature. 2017 May 24;545(7655):423-431
pubmed: 28541315
J Immunol. 2016 Jan 15;196(2):759-66
pubmed: 26673145
Mol Pharm. 2015 Jun 1;12(6):2151-7
pubmed: 25955255
Ther Adv Med Oncol. 2020 Mar 9;12:1758835920910347
pubmed: 32215059
Hepatology. 2018 Aug;68(2):574-589
pubmed: 29443377
Int J Oncol. 2018 Jan;52(1):219-230
pubmed: 29138811
J Gastroenterol Hepatol. 2006 Aug;21(8):1281-5
pubmed: 16872310
Cancer Res. 2008 Mar 1;68(5):1451-61
pubmed: 18316609
Cancer Res. 2015 Sep 1;75(17):3596-607
pubmed: 26330166
Mol Ther Nucleic Acids. 2013 Aug 13;2:e114
pubmed: 23941866
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Hepatol. 2006 Aug;45(2):246-53
pubmed: 16580084
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Cancer Treat Rev. 2018 Jun;67:54-62
pubmed: 29763778
Sci Rep. 2017 Oct 30;7(1):14366
pubmed: 29085043
Front Immunol. 2020 Apr 22;11:702
pubmed: 32391013
Clin Cancer Res. 2018 Apr 1;24(7):1518-1524
pubmed: 29138342
Blood Adv. 2020 Nov 10;4(21):5414-5424
pubmed: 33147337
Cancer. 1988 Aug 1;62(3):479-83
pubmed: 2839280
JCI Insight. 2018 Jan 11;3(1):
pubmed: 29321369
ESMO Open. 2020 Aug;4(Suppl 4):
pubmed: 32839196
Science. 2020 Feb 28;367(6481):
pubmed: 32029687
J Clin Oncol. 2020 Nov 10;38(32):3794-3804
pubmed: 32701411
Br J Cancer. 2015 Jun 9;112(12):1911-20
pubmed: 26057582
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358